The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 12, 2025

Filed:

Jun. 21, 2023
Applicant:

Cephalon Llc, West Chester, PA (US);

Inventors:

Anna Mikaela Bracken, Lane Cove, AU;

Adam Clarke, Riverstone, AU;

Bridget A. Cooksey, Curl Curl, AU;

Anthony Gerard Doyle, Macquarie Park, AU;

Mark Terence Liddament, Victoria, AU;

Matthew Pollard, Pullenvale, AU;

Lynn Poulton, Macquarie Park, AU;

Anna Maria Matilda Quigley, Macquarie Park, AU;

Julia Rozenfeld, Macquarie Park, AU;

Marta Szabat, Vancouver, CA;

Assignee:

Cephalon LLC, West Chester, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); A61P 17/10 (2006.01); A61P 29/00 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61P 17/10 (2018.01); A61P 29/00 (2018.01); A61P 35/04 (2018.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).


Find Patent Forward Citations

Loading…